New Releases from NCBI BookshelfAvapritinib (Ayvakyt): Indication: For the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL): Reimbursement Recommendation [Internet].​Avapritinib (Ayvakyt): Indication: For the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL): Reimbursement Recommendation [Internet].